about
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemiaRecognition and management of childhood cancer syndromes: a systems approach.Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.Nuclear accumulation of beta-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomasWt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation.Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumorWT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1)Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor.A high incidence of WT1 abnormality in bilateral Wilms tumours in Japan, and the penetrance rates in children with WT1 germline mutationExpanding the phenotype of mutations in DICER1: mosaic missense mutations in the RNase IIIb domain of DICER1 cause GLOW syndrome.β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.Array CGH Analysis of Paired Blood and Tumor Samples from Patients with Sporadic Wilms TumorClinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.Identification of germline DICER1 mutations and loss of heterozygosity in familial Wilms tumour.Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical featuresImmunohistochemical Characterization of a Renal Nephroblastoma in a Trp53-mutant and Prolyl Isomerase 1-deficient Mouse.Candidate genes and potential targets for therapeutics in Wilms' tumour.Somatic glypican 3 (GPC3) mutations in Wilms' tumour.Multicenter study identified molecular blood-born protein signatures for Wilms Tumor.Silencing of hypoxia inducible factor-1α by RNA interference inhibits growth of SK-NEP-1 Wilms tumour cells in vitro, and suppresses tumourigenesis and angiogenesis in vivo.The predictive value of transforming growth factor-β in Wilms tumor immunopathogenesis.Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants.Associations between LMO1 gene polymorphisms and Wilms' tumor susceptibility.K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.Integration of Cistromic and Transcriptomic Analyses Identifies Nphs2, Mafb, and Magi2 as Wilms' Tumor 1 Target Genes in Podocyte Differentiation and Maintenance.Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.Defects in the DNA mismatch repair system do not contribute to the development of childhood wilms tumors.Biallelic DICER1 mutations occur in Wilms tumours.Pharmacologic Inhibition of β-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor.Characterization of primary Wilms tumor cultures as an in vitro model.Evaluation of chromosome 11p imbalances in aniridia and Wilms tumor patients.Renal TumorsBilateral Wilms Tumor: A Surgical Perspective
P2860
Q26744111-56C10CEE-6C05-4B48-A128-1F92DCDE5CEAQ33772586-088B6338-6346-483E-9ED4-0EF3B23E5CD6Q34010180-721CDC3B-095E-4AC6-BC95-138F5482679CQ34346138-D637B9A2-C93F-4B63-B1DE-92D2B74CB9D4Q34428960-7AB0A1BB-9CDD-4496-A697-85521B6E4203Q34525911-1E7495E0-105D-47FE-BCA7-4D54CA18CAE3Q34667826-6A6AE578-3FA0-4D9C-9ABC-B288999EAE19Q34901968-626D0EC6-8CAC-44C9-BF07-A8291772515AQ35005638-CFA6C5A7-80C6-47E7-A3B2-9C05C3EC9A25Q35095712-657A77DB-9D49-48C8-AFEE-5833DB379AB5Q35098009-FF8021C3-0033-4D70-9426-5CA5AC9F4CCFQ35198305-3EDFD81B-D056-4CEA-BA44-4BDC3428FDAEQ35600539-302F28CA-4A05-4AC1-8700-E14CAE838982Q35679310-3ED2B76F-4C63-486C-A981-FBD5C22B0680Q35759070-ADDFB946-2164-469E-ABE5-31E60ED32B9DQ36200428-C6099504-0C52-45C7-9DF3-AD82BC551D76Q36900924-15E35153-5F54-4609-BD23-4EA70E0E5DE3Q37435558-8DBD9E65-6EDE-407D-BEE2-FA4E03699993Q37579378-E76DFE9B-D43B-4EA3-9360-C8CDBC8CFBD6Q37790163-7C3AD984-5B74-4BE8-A78F-9E36F07B9890Q38283630-82153686-E0C2-47F0-93E8-B3E6B97BC475Q38331911-7A874664-2A9B-4D87-B85C-74E690645755Q38783142-B547A3E5-1E67-46F9-84FB-A8B85B2BA879Q39290714-048C8211-48F7-49ED-A486-E486B99B9514Q39642614-8BC4CCC7-FBE1-4137-A6BB-C6185E011168Q40053313-791ECD62-CFFE-4D58-B936-C4EC5D7BDABDQ40429284-3D9FCE7A-09C0-4D54-B70D-531A6605C90CQ41629547-6557A806-954F-467F-B70E-EF428C3C73BAQ42274969-C21B86DF-6BAC-4A35-B789-62C04A232A3FQ42277975-33B0F92E-B5AD-40BF-A998-D03279687263Q44319548-1731A642-EA9C-4386-90F4-09FBA848525CQ46977021-C4123FA5-D7CD-41CC-BD78-C9BC1A2B8851Q47110433-DD858E13-EE42-40E9-BAA5-29CD661FD347Q51849264-11AF4A07-5B39-452F-B2B6-CCAF5D92DF19Q54268320-3887051C-ADC2-4C28-AE16-F7397FAA684DQ57339611-0A19F905-5EDD-4129-9EC9-FF5D42299945Q58699666-5F516A02-8DDD-43B6-AA25-8A95F49EA258
P2860
description
1998 nî lūn-bûn
@nan
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Wilms tumor genetics.
@ast
Wilms tumor genetics.
@en
Wilms tumor genetics.
@nl
type
label
Wilms tumor genetics.
@ast
Wilms tumor genetics.
@en
Wilms tumor genetics.
@nl
prefLabel
Wilms tumor genetics.
@ast
Wilms tumor genetics.
@en
Wilms tumor genetics.
@nl
P2860
P1476
Wilms tumor genetics.
@en
P2093
P2860
P304
P356
10.1002/(SICI)1096-8628(19981002)79:4<260::AID-AJMG6>3.0.CO;2-Q
P577
1998-10-01T00:00:00Z